Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors

Journal of Thoracic Oncology

Volumn 9, Issue 3, 2014, Pages 316-323

  Jänne, Pasi A ^a   Cohen, Roger B ^b   Laird, A Douglas ^c   Macé, Sandrine ^d   Engelman, Jeffrey A ^e   Ruiz Soto, Rodrigo ^f   Rockich, Kevin ^g   Xu, Jianbo ^h   Shapiro, Geoffrey I ^a   Martinez, Pablo ⁱ   Felip, Enriqueta ⁱ  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c EXELIXIS INC   (United States)

^d SANOFI   (France)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f Clinical Development   (United States)

^g Navartis   (United States)

^h Biostatistics   (United States)

ⁱ Vall d'ebron University Hospital   (Spain)

Author keywords

Advanced solid tumors; Epidermal growth factor receptor inhibitor; Pharmacodynamics; Pharmacokinetics; PI3K mammalian target of rapamycin inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ERLOTINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SAR 245409; UNCLASSIFIED DRUG; XL 765;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DECREASED APPETITE; DERMATITIS; DIARRHEA; DRESS SYNDROME; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; DYSPNEA; ENZYME REPRESSION; FATIGUE; FEMALE; HUMAN; LUNG CANCER; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN; SOLID TUMOR; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; QUINOXALINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SAFETY; SULFONAMIDES; SURVIVAL RATE; TISSUE DISTRIBUTION; TOR SERINE-THREONINE KINASES;

EID: 84894589324     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000088     Document Type: Article

References (23)

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657.
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-619.
3. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009;102:19-65.
4. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-644.
5. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-1083.
6. Cortot AB, Repellin CE, Shimamura T, et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res 2013;73:834-843.
7. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043.
8. Donev IS, Wang W, Yamada T, et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 2011;17:2260-2269.
9. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-Amplified lung cancer. J Clin Invest 2006;116:2695-2706.
10. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
11. Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 2010;29:5193-5203.
12. Faber AC, Li D, Song Y, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009;106:19503-19508.
13. Klein S, Levitzki A. Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol 2009;21:185-193.
14. Priulla M, Calastretti A, Bruno P, et al. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate 2007;67:782-789.
15. Santiskulvong C, Konecny GE, Fekete M, et al. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 2011;17:2373-2384.
16. Li B, Gao S, Wei F, Bellail AC, Hao C, Liu T. Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells. Oncol Rep 2012;28:15-20.
17. Laird AD. XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR [Abstract]. In Proceedings of the Molecular Targets and Cancer Therapeutics Conference San Francisco, CA: October 22-26, 2007; 241.
18. Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 2010;1:530-543.
19. Markman B, Atzori F, Pérez-García J, Tabernero J, Baselga J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2010;21:683-691.
20. U.S. Department of Health and Human Services, National Cancer Institute & National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. 2006.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
22. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13:5150-5155.
23. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-599.